Last reviewed · How we verify
NCT07065981
Upper Limb Exercise Capacity: Lung Transplant vs. Healthy Controls
trial in Transplant Recipient in 60 participants. Completed in 15 September 2025.
15 September 2025
Quick facts
| Lead sponsor | Ankara City Hospital Bilkent |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 25 June 2025 |
| Primary completion | 15 September 2025 |
| Estimated completion | 15 September 2025 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Transplant Recipient — all drugs for Transplant Recipient →
Sponsor
Ankara City Hospital Bilkent
Who can join
Adults 18 to 70, any sex, with Transplant Recipient. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lung transplantation is a surgical intervention for end-stage lung diseases (e.g., COPD, cystic fibrosis, idiopathic pulmonary fibrosis). While post-transplant pulmonary function improves, peak exercise capacity remains 40-60% lower than age-matched healthy individuals due to factors like muscle weakness, reduced aerobic capacity, and immunosuppressive therapy. Although lower extremity rehabilitation is common, upper extremity (UE) function is often overlooked despite its impact on quality of life (QoL) and activities of daily living (ADLs). The 6-Minute Pegboard and Ring Test (6PBRT) evaluates UE functional capacity but has not been studied in long-term lung transplant recipients (LTRs). Objectives: Primary: Compare UE exercise capacity between LTRs and healthy controls using 6PBRT. Secondary: Investigate correlations between 6PBRT performance and pulmonary function, fatigue perception, ADLs, and QoL in LTRs. Hypotheses: H0: No significant difference in UE exercise capacity between LTRs and healthy individuals. H1: Significant difference exists. Methods: Design: Cross-sectional study. Sample size calculated based on prior 6PBRT data (effect size: 1.10, power: 80%, α: 0.05). Assessments: Demographics: Age, sex, BMI, Charlson Comorbidity Index (CCI). 6PBRT: Measures UE endurance (total rings moved in 6 minutes). Vital signs (SpO₂, heart rate, Borg scale for fatigue) recorded. LTR-specific: Pulmonary function: FEV₁, FVC, FEV₁/FVC. Fatigue: Fatigue Severity Scale (FSS; scores ≥4 indicate severe fatigue). QoL: St. George's Respiratory Questionnaire (SGRQ; 0=best, 100=worst). ADLs: London Chest ADL Questionnaire (0-5 scale). Expected Outcomes: LTRs will show significantly lower 6PBRT scores vs. controls. 6PBRT performance will correlate with pulmonary function, fatigue, and QoL in LTRs.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07065981
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Transplant Recipient
Currently open trials in the same condition.
- NCT05410496 — Tenofovir Alafenamide Switching Therapy in Kidney or Liver Transplant Recipients With Chronic HBV Infection · Phase 4 · active not recruiting
Other Ankara City Hospital Bilkent trials
Trials by the same sponsor.
- NCT07496788 — Investigation of the Role of Internal Jugular Vein Collapsibility Index in Predicting Spinal Anesthesia-Induced Hypotens · not yet recruiting
- NCT07536464 — PEEP Strategies and Mechanical Power in Robotic Surgery · NA · not yet recruiting
- NCT07534553 — Mechanical Power Ventilation in RALP · NA · not yet recruiting
- NCT07501468 — Ventilation Safety in Beach Chair Shoulder Surgery: SafeLM Versus I-gel · NA · not yet recruiting
- NCT07502209 — Suprascapular Nerve PRF in Chronic Shoulder Pain · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07065981 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara City Hospital Bilkent
- Last refreshed: 19 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07065981.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing